Literature DB >> 21196180

The regulation of cell growth and survival by aldosterone.

Ruth Dooley1, Brian J Harvey, Warren Thomas.   

Abstract

The steroid hormone aldosterone is synthesized from cholesterol, mainly in the zona glomerulosa of the adrenal cortex. Aldosterone exerts its effects in the epithelial tissues of the kidney and colon and in non-epithelial tissues such as the brain and cardiovasculature. The genomic response to aldosterone involves dimerization of the mineralocorticoid receptor (MR), dissociation of heat shock proteins from MR, translocation of the aldosterone-MR complex to the nucleus and the concomitant regulation of gene expression. Rapid responses to aldosterone occur within seconds to minutes, do not involve transcription or translation and can modulate directly or indirectly the later genomic responses. Aside from the well-known effects of aldosterone on the regulation of sodium and water homeostasis, aldosterone can also produce deleterious structural changes in tissues by inducing hypertrophy and the dysregulation of proliferation and apoptosis, leading to fibrosis and tissue remodelling. Here we discuss the involvement of aldosterone-mediated rapid signalling cascades in the development of disease states such as chronic kidney disease and heart failure, and the antagonists that can inhibit these pathophysiological responses.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21196180     DOI: 10.2741/3697

Source DB:  PubMed          Journal:  Front Biosci (Landmark Ed)        ISSN: 2768-6698


  9 in total

Review 1.  HDAC-dependent ventricular remodeling.

Authors:  Min Xie; Joseph A Hill
Journal:  Trends Cardiovasc Med       Date:  2013-03-15       Impact factor: 6.677

Review 2.  Finerenone: a New Mineralocorticoid Receptor Antagonist Without Hyperkalemia: an Opportunity in Patients with CKD?

Authors:  Hermann Haller; Anna Bertram; Klaus Stahl; Jan Menne
Journal:  Curr Hypertens Rep       Date:  2016-04       Impact factor: 5.369

3.  Elevation of the antifibrotic peptide N-acetyl-seryl-aspartyl-lysyl-proline: a blood pressure-independent beneficial effect of angiotensin I-converting enzyme inhibitors.

Authors:  Megumi Kanasaki; Takako Nagai; Munehiro Kitada; Daisuke Koya; Keizo Kanasaki
Journal:  Fibrogenesis Tissue Repair       Date:  2011-11-30

Review 4.  N-acetyl-seryl-aspartyl-lysyl-proline: a valuable endogenous anti-fibrotic peptide for combating kidney fibrosis in diabetes.

Authors:  Keizo Kanasaki; Takako Nagai; Kyoko Nitta; Munehiro Kitada; Daisuke Koya
Journal:  Front Pharmacol       Date:  2014-04-14       Impact factor: 5.810

5.  Extracellular Na(+) levels regulate formation and activity of the NaX/alpha1-Na(+)/K(+)-ATPase complex in neuronal cells.

Authors:  Emmanuelle Berret; Pascal Y Smith; Mélaine Henry; Denis Soulet; Sébastien S Hébert; Katalin Toth; Didier Mouginot; Guy Drolet
Journal:  Front Cell Neurosci       Date:  2014-12-04       Impact factor: 5.505

6.  A Single Nucleotide Polymorphism near the CYP17A1 Gene Is Associated with Left Ventricular Mass in Hypertensive Patients under Pharmacotherapy.

Authors:  Matthias Huber; Susanne Lezius; Rona Reibis; Andras Treszl; Dorota Kujawinska; Stefanie Jakob; Karl Wegscheider; Heinz Völler; Reinhold Kreutz
Journal:  Int J Mol Sci       Date:  2015-07-30       Impact factor: 5.923

7.  Similar to spironolactone, oxymatrine is protective in aldosterone-induced cardiomyocyte injury via inhibition of calpain and apoptosis-inducing factor signaling.

Authors:  Ting-Ting Xiao; Yuan-Yuan Wang; Yan Zhang; Cong-Hui Bai; Xiang-Chun Shen
Journal:  PLoS One       Date:  2014-02-13       Impact factor: 3.240

Review 8.  Dysregulation of histone acetyltransferases and deacetylases in cardiovascular diseases.

Authors:  Yonggang Wang; Xiao Miao; Yucheng Liu; Fengsheng Li; Quan Liu; Jian Sun; Lu Cai
Journal:  Oxid Med Cell Longev       Date:  2014-02-18       Impact factor: 6.543

9.  Eplerenone attenuated cardiac steatosis, apoptosis and diastolic dysfunction in experimental type-II diabetes.

Authors:  Elisa Ramírez; Mercedes Klett-Mingo; Sara Ares-Carrasco; Belén Picatoste; Alessia Ferrarini; Francisco J Rupérez; Alicia Caro-Vadillo; Coral Barbas; Jesús Egido; José Tuñón; Óscar Lorenzo
Journal:  Cardiovasc Diabetol       Date:  2013-11-21       Impact factor: 9.951

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.